Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.
Details